Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Unknown 4Recruiting 2Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 17Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Lung Neoplasms 7Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Ovarian Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Neoplasms, Basal Cell 1Muscle-Invasive Bladder Carcinoma 1Metastatic Pancreatic Ductal Adenocarcinoma 1Metastatic Pancreatic Adenocarcinoma 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 16Radiotherapy 15Drug Therapy 14Paclitaxel 13Cisplatin 12Carboplatin 10Immunotherapy 9Esophagectomy 9Radiation 8Fluorouracil 8Surgical Procedures, Operative 7Capecitabine 7Blood Specimen Collection 7Oxaliplatin 6Nivolumab 6Immune Checkpoint Inhibitors 6Chemoradiotherapy 6nimotuzumab 5Trastuzumab 5130-nm albumin-bound paclitaxel 5sintilimab 4camrelizumab 4Leucovorin 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Surveys and Questionnaires 3Endoscopy 3Bevacizumab 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Esophageal Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT04278287 2024-12-13

Chemoradiotherapy in Unresectable Esophageal Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Recruiting
105 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT06663059 2024-10-29

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

Tang-Du Hospital

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡